Patents by Inventor Daniel B. DIX

Daniel B. DIX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS
    Publication number: 20190388539
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 26, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20190367624
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 10472425
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 12, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
    Patent number: 10435473
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: October 8, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang
  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20190284301
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 15, 2019
    Publication date: September 19, 2019
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Method of manufacturing VEGF antagonist fusion proteins
    Patent number: 10406226
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20190002574
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 3, 2019
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 10072086
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 11, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20180044436
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: May 24, 2017
    Publication date: February 15, 2018
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20180002426
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: February 3, 2017
    Publication date: January 4, 2018
    Inventors: Daniel B. Dix, Xiaolin Tang
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20170360930
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF specific fusion protein antagonist formulations
    Patent number: 9636400
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: May 2, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20170073407
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 16, 2017
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 9580489
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: February 28, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel B. Dix, Kenneth Graham, Kelly Frye
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20160244504
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 10, 2016
    Publication date: August 25, 2016
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20160244505
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 11, 2016
    Publication date: August 25, 2016
    Inventors: Eric FURFINE, Daniel B. DIX, Kenneth GRAHAM, Kelly FRYE
  • Stabilized formulations containing anti-Ang2 antibodies
    Patent number: 9402898
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: August 2, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20160102147
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: December 9, 2015
    Publication date: April 14, 2016
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20160032015
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 4, 2016
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
    Patent number: 9238692
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 19, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang